Immunoengineering Next-Generation Cancer Therapies with Focused Ultrasound
聚焦超声免疫工程下一代癌症疗法
基本信息
- 批准号:10254496
- 负责人:
- 金额:$ 40.38万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2021
- 资助国家:美国
- 起止时间:2021-09-14 至 2026-08-31
- 项目状态:未结题
- 来源:
- 关键词:AcousticsAdjuvantAdministratorAppointmentAuthorshipBiomedical EngineeringBiopsy SpecimenBlood ScreeningBreast Cancer PatientBreast Cancer therapyBreast cancer metastasisCAR T cell therapyCD8-Positive T-LymphocytesCancer EtiologyCancer PrognosisCessation of lifeClinicalClinical ProtocolsClinical TrialsCollaborationsCombination immunotherapyCompanionsDataDepositionDiagnostic radiologic examinationDiseaseDrug Delivery SystemsEngineeringExtramural ActivitiesFellowshipFocused UltrasoundFoundationsFundingGenomicsGoalsHRK geneHomeHuman ResourcesImageImaging TechniquesImmuneImmunoPETImmunologicsImmunologyImmunooncologyImmunotherapyInfrastructureInstitutional Review BoardsInternationalInterventionKnowledgeLesionMachine LearningMapsMechanicsMediatingMentorsMentorshipMetastatic breast cancerMetastatic malignant neoplasm to brainMolecularMonitorMultimodal ImagingMusMyelogenousOutcomePD-1 blockadePET/CT scanPatientsPeer ReviewPeripheralPlant RootsPlayPositioning AttributePostdoctoral FellowPrecision therapeuticsPublicationsRadiogenomicsRadiology SpecialtyRecurrenceRegimenResearchResearch TrainingResourcesRoleSolid NeoplasmStructureT-LymphocyteTechniquesTechnologyTestingTherapeuticTimeTrainingTranslatingTranslational ResearchTranslationsTreatment EfficacyTumor MarkersTumor TissueTumor-infiltrating immune cellsUltrasonographyUnited StatesUnited States National Institutes of HealthUniversitiesUniversity of Virginia Cancer CenterVirginiaWomanadaptive immune responseadaptive immunityadvanced breast canceranti-PD-1anti-tumor immune responsebasebioimagingbiomarker discoverycancer biomarkerscancer genomicscancer immunotherapycancer therapycancer typecareerchemotherapychimeric antigen receptorchimeric antigen receptor T cellscirculating biomarkerscombinatorialdesignexosomefaculty researchfirst-in-humangemcitabinegenomic datagenomic signaturegraduate studentimaging informaticsimmunoengineeringimmunogenicityimprovedinnovationliquid biopsymalignant breast neoplasmmembermolecular imagingmortalitynext generationnovelnovel markerpersonalized immunotherapypersonalized medicinepre-clinicalprecision oncologypreclinical studypredict clinical outcomepredicting responseprognosticprogramsquantumradiomicsresponseresponse biomarkerrisk stratificationsenior facultyskillstargeted treatmenttenure tracktheranosticstooltrial designtumortumor DNA
项目摘要
Project Abstract
Metastatic breast cancer (BrCa) is the 2nd most prevalent cause of cancer mortality in women in the United
States, with a 5-year overall survival of only 22%. Though cancer immunotherapies are capable of generating
durable responses across a variety of cancer types, immunologic rejection of BrCa is rare and spontaneous
regression unusual. Thus, there exists a strong precedent for allied combinatorial therapy paradigms that
potentiate immunotherapy (ITx) by boosting tumor immunogenicity and/or curbing immunosuppressive
mechanisms. In this proposal, we will systematically assess the capacity of focused ultrasound (FUS) - a
technique for non-invasive, non-ionizing acoustic energy deposition into tumors – to potentiate adaptive immunity
against BrCa metastases and synergize with selected immunotherapies. UVA is a world leader in FUS ITx
research, with two “first-in-human” clinical trials underway to evaluate combinations of FUS with PD1 blockade
in solid tumors (including metastatic BrCa) and a third trial pending approval to evaluate FUS and gemcitabine
for immune-mediated control of BrCa tumors. These trials are accompanied by a companion imaging trial
designed to evaluate CD8+ T cell infiltration in patients’ tumor deposits via PET/CT, an approach that will also
be integrated into our pre-clinical studies. To this end, this proposal leverages these clinical trials as well as a
robust pre-clinical program to fortify a highly translational research pipeline rooted in the domains of immunology,
molecular imaging, liquid biopsy and radiogenomics. With this toolkit, we intend to design and implement
FUS+ITx combinations that offer the potential for quantum improvements in metastatic BrCa therapy. This is
achieved in three Specific Aims. In Specific Aim 1, we will expand on intriguing early clinical and pre-clinical
findings to identify FUS regimens that, when combined with myeloid-targeted therapies, augment the efficacy of
chimeric antigen receptor (CAR) T cell therapy against primary and disseminated BrCa tumors (e.g. brain
metastases). In Specific Aim 2, we will engineer FUS-based theranostic technologies for liquid biopsy in BrCa in
order to (i) discover novel biomarkers of response to FUS and ITx (ii) enable liquid biopsy in settings with low
basal levels of circulating tumor biomarkers. Finally, in Specific Aim 3, we will construct machine learning
frameworks that integrate radiological data with genomic data from liquid biopsy specimens (e.g. radiogenomics)
to advance BrCa precision care with FUS and ITx. The highly innovate aims of this proposal lend to a systematic
approach for advancing the role of FUS in CAR T cell therapy, cancer biomarker discovery and personalized
ITx, thereby promising to improve the lives of metastatic breast cancer patients.
项目摘要
转移性乳腺癌(BrCa)是美国女性癌症死亡的第二大常见原因。
美国,5年总生存率仅为22%。尽管癌症免疫疗法能够产生
BrCa在多种癌症类型中具有持久的反应,但BrCa的免疫排斥反应罕见且自发
退化异常。因此,对于联合组合疗法范例存在强有力的先例,
通过增强肿瘤免疫原性和/或抑制免疫抑制性来增强免疫疗法(ITx)
机制等在本提案中,我们将系统地评估聚焦超声(FUS)的能力-a
用于非侵入性、非电离声能沉积到肿瘤中技术-以增强适应性免疫
针对BrCa转移,并与选定的免疫疗法协同作用。UVA是FUS ITx的全球领导者
研究,两项"首次在人体"的临床试验正在进行中,以评估FUS与PD1阻断剂的组合
在实体瘤(包括转移性BrCa)和第三项试验中评估FUS和吉西他滨,
用于免疫介导的BrCa肿瘤控制。这些试验都伴随着一个同伴成像试验
旨在通过PET/CT评估患者肿瘤沉积物中的CD8 + T细胞浸润,该方法还将
纳入我们的临床前研究。为此,该提案利用这些临床试验以及
强大的临床前计划,以加强植根于免疫学领域的高度转化研究管道,
分子成像、液体活检和放射基因组学。有了这个工具包,我们打算设计和实现
FUS + ITx组合,可提供转移性BrCa治疗的量子改善潜力。这是
实现三个具体目标。在具体目标1中,我们将扩展有趣的早期临床和临床前
研究结果确定FUS方案,当与骨髓靶向治疗联合使用时,
针对原发性和播散性BrCa肿瘤(例如脑肿瘤)的嵌合抗原受体(CAR)T细胞疗法
转移)。在具体目标2中,我们将设计基于FUS的治疗诊断技术,用于BrCa的液体活检,
为了(i)发现对FUS和ITx反应的新生物标志物(ii)在低浓度的环境中进行液体活检,
循环肿瘤生物标志物的基础水平。最后,在具体目标3中,我们将构建机器学习
将放射学数据与来自液体活检标本的基因组数据相结合的框架(例如放射基因组学)
通过FUS和ITx推进BrCa精准护理。这一建议的高度创新目标有助于系统地
推进FUS在CAR T细胞治疗、癌症生物标志物发现和个性化治疗中的作用的方法
ITx,从而有望改善转移性乳腺癌患者的生活。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Natasha Diba Sheybani其他文献
Natasha Diba Sheybani的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Natasha Diba Sheybani', 18)}}的其他基金
Immunoengineering Next-Generation Cancer Therapies with Focused Ultrasound
聚焦超声免疫工程下一代癌症疗法
- 批准号:
10693947 - 财政年份:2021
- 资助金额:
$ 40.38万 - 项目类别:
Focused Ultrasound and Multifunctional Nanoparticle Vaccines as Adjuvant Strategies for Cancer Immunotherapy
聚焦超声和多功能纳米颗粒疫苗作为癌症免疫治疗的辅助策略
- 批准号:
10252068 - 财政年份:2020
- 资助金额:
$ 40.38万 - 项目类别:
相似海外基金
Metachronous synergistic effects of preoperative viral therapy and postoperative adjuvant immunotherapy via long-term antitumor immunity
术前病毒治疗和术后辅助免疫治疗通过长期抗肿瘤免疫产生异时协同效应
- 批准号:
23K08213 - 财政年份:2023
- 资助金额:
$ 40.38万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Improving the therapeutic immunity of cancer vaccine with multi-adjuvant polymeric nanoparticles
多佐剂聚合物纳米粒子提高癌症疫苗的治疗免疫力
- 批准号:
2881726 - 财政年份:2023
- 资助金额:
$ 40.38万 - 项目类别:
Studentship
Countering sympathetic vasoconstriction during skeletal muscle exercise as an adjuvant therapy for DMD
骨骼肌运动期间对抗交感血管收缩作为 DMD 的辅助治疗
- 批准号:
10735090 - 财政年份:2023
- 资助金额:
$ 40.38万 - 项目类别:
Evaluation of the Sensitivity to Endocrine Therapy (SET ER/PR) Assay to predict benefit from extended duration of adjuvant endocrine therapy in the NSABP B-42 trial
NSABP B-42 试验中内分泌治疗敏感性 (SET ER/PR) 测定的评估,用于预测延长辅助内分泌治疗持续时间的益处
- 批准号:
10722146 - 财政年份:2023
- 资助金额:
$ 40.38万 - 项目类别:
AUGMENTING THE QUALITY AND DURATION OF THE IMMUNE RESPONSE WITH A NOVEL TLR2 AGONIST-ALUMINUM COMBINATION ADJUVANT
使用新型 TLR2 激动剂-铝组合佐剂增强免疫反应的质量和持续时间
- 批准号:
10933287 - 财政年份:2023
- 资助金额:
$ 40.38万 - 项目类别:
DEVELOPMENT OF SAS A SYNTHETIC AS01-LIKE ADJUVANT SYSTEM FOR INFLUENZA VACCINES
流感疫苗类 AS01 合成佐剂系统 SAS 的开发
- 批准号:
10935776 - 财政年份:2023
- 资助金额:
$ 40.38万 - 项目类别:
DEVELOPMENT OF SMALL-MOLECULE DUAL ADJUVANT SYSTEM FOR INFLUENZA VIRUS VACCINE
流感病毒疫苗小分子双佐剂体系的研制
- 批准号:
10935796 - 财政年份:2023
- 资助金额:
$ 40.38万 - 项目类别:
A GLYCOLIPID ADJUVANT 7DW8-5 FOR MALARIA VACCINES
用于疟疾疫苗的糖脂佐剂 7DW8-5
- 批准号:
10935775 - 财政年份:2023
- 资助金额:
$ 40.38万 - 项目类别:
Adjuvant strategies for universal and multiseasonal influenza vaccine candidates in the context of pre-existing immunity
在已有免疫力的情况下通用和多季节流感候选疫苗的辅助策略
- 批准号:
10649041 - 财政年份:2023
- 资助金额:
$ 40.38万 - 项目类别:
Adjuvant Photodynamic Therapy to Reduce Bacterial Bioburden in High-Energy Contaminated Open Fractures
辅助光动力疗法可减少高能污染开放性骨折中的细菌生物负载
- 批准号:
10735964 - 财政年份:2023
- 资助金额:
$ 40.38万 - 项目类别: